Pancreatic Cancer Research

ResearcherHokkaido UniversityNo recent work listed

Hirofumi Kamachi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2742-245X; OpenAlex author ID A5015142274. Sources: OpenAlex.

Their work

Papers
9 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 4 papers · 2019: none · 2020: none · 2021: 2 papers · 2022: 1 paper

Papers 9

  1. HOPS-R01 phase II trial evaluating neoadjuvant S-1 therapy for resectable pancreatic adenocarcinoma. Co-author DOI 10.1038/s41598-022-14094-0↗
  2. Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreat… First author DOI 10.1007/s10637-021-01118-1↗
  3. Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive panc… First author DOI 10.1186/s12885-020-07722-3↗
  4. Pancreaticoduodenectomy with Preservation of Collateral Circulation or Revascularization for Biliary Pancreatic Cancer with Celiac Axis Occlusion: A Report of … First author DOI 10.12659/ajcr.908516↗
  5. The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in … First author DOI 10.18632/oncotarget.26117↗
  6. R0 Resection for Locally Advanced Pancreatic Cancer with Low-dose Gemcitabine with Wide Irradiation Area as Neoadjuvant Chemoradiotherapy. Co-author DOI 10.21873/invivo.11362↗
  7. Curative resection of pancreatic ductal adenocarcinoma developing in the remnant pancreas 13 years after distal pancreatectomy for intraductal papillary mucino… First author DOI 10.3892/mco.2018.1556↗
  8. Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy. First author DOI 10.1186/1471-2407-14-687↗
  9. Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. First author DOI 10.1097/mpa.0b013e318221bed8↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Akinobu Taketomi · 8 shared papers, 2014–2022 · strength 0.73
  2. Tatsuzo Mizukami · 4 shared papers, 2014–2021 · strength 0.40
  3. Fumihiko Matsuzawa · 3 shared papers, 2018–2021 · strength 0.36
  4. Takahiro Einama · 4 shared papers, 2011–2021 · strength 0.30
  5. Yuki Fujii · 2 shared papers, 2021 · strength 0.28
  6. Kazuaki Shibuya · 2 shared papers, 2018 · strength 0.15
  7. Junpei Sasajima · 1 shared paper, 2022 · strength 0.10
  8. Yohei Kitano · 1 shared paper, 2022 · strength 0.10
  9. Tsuyoshi Hayashi · 1 shared paper, 2022 · strength 0.10
  10. Masafumi Imamura · 1 shared paper, 2022 · strength 0.10
  11. Hirotoshi Ishiwatari · 1 shared paper, 2022 · strength 0.10
  12. Shin Haba · 1 shared paper, 2022 · strength 0.10
  13. Yasutoshi Kimura · 1 shared paper, 2022 · strength 0.10
  14. Tõru Nakamura · 1 shared paper, 2022 · strength 0.10
  15. Tomoya Iida · 1 shared paper, 2022 · strength 0.10
  16. Satoshi Hirano · 1 shared paper, 2022 · strength 0.10
  17. Masayo Motoya · 1 shared paper, 2022 · strength 0.10
  18. Yuki Fujii · 1 shared paper, 2018 · strength 0.08
  19. Norio Katoh · 1 shared paper, 2018 · strength 0.08
  20. Yosuke Tsuruga · 1 shared paper, 2014 · strength 0.04
  21. Satoru Todo · 1 shared paper, 2011 · strength 0.02
  22. Michitaka Ozaki · 1 shared paper, 2011 · strength 0.02
  23. Hiroshi Nishihara · 1 shared paper, 2011 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.